TacticScaleWhat Gilead Sciences Does & How It Makes Money (GILD)
Updated October 2026 · reflects Gilead Sciences's latest reported financials
Biopharma company making HIV, liver disease, and cancer medicines. Gilead earns revenue by selling patented branded medicines, mainly HIV drugs plus liver disease, oncology, and antiviral products, to healthcare systems worldwide.
How Gilead Sciences makes money
Gilead earns revenue by selling patented branded medicines, mainly HIV drugs plus liver disease, oncology, and antiviral products, to healthcare systems worldwide. It adds to its pipeline through collaboration and licensing deals with other biotech and pharma companies.
What Gilead Sciences does
Gilead Sciences, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company best known for HIV medicines. Its HIV portfolio includes treatments such as Biktarvy, Descovy, Genvoya, Odefsey, Symtuza, and Sunlenca, plus Yeztugo (lenacapavir). Gilead is partnering with the Pan American Health Organization to expand access to lenacapavir for HIV prevention (PrEP) across Latin America and the Caribbean. Its liver disease medicines include Epclusa for hepatitis C, Vemlidy for hepatitis B, and Livdelzi for primary biliary cholangitis. In oncology, Gilead sells the CAR T-cell therapies Yescarta and Tecartus and the intravenous cancer drug Trodelvy. It is developing further immunotherapies for cancer and other incurable diseases. It also sells AmBisome for serious fungal infections and Veklury for COVID-19. Gilead builds its pipeline through many collaborations, including deals with Merck, Arcus Biosciences, Merus, LEO Pharma, and Terray Therapeutics.
Products & services
- Biktarvy
- Descovy
- Yeztugo
- Epclusa
- Yescarta
- Trodelvy
What is Gilead Sciences worth?
On an owner-earnings DCF, Gilead Sciences's most-likely value is about $189 versus a recent price near $151 (25% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$113) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Vir Biotechnology (VIR) · Ligand Pharmaceuticals (LGND) · Eli Lilly and (LLY) · Bio-Thera Solutions (688177.SS)